Bioequivalence and Bioavailability Forum

❝ I had a question related to the homoscedasticity assumption in the RSABE method when I read the tutorial of PowerTOST.

❝ PowerTOST-RSABE

❝ If the RSABE method is performed on the highly variable drug with the 4-way crossover design (not the NTI drug), is the homoscedasticity assumption always holden? And I think if a 3-way crossover design is used, there is no way to assume the homoscedasticity since the test drug is administered once and we can not calculate the WSV of the test drug.

❝

Hello all,

I also have a similar question regarding calculation of s²_wT (mentioned in this article about SABE based on the CVw of a Crossover Design). In the article the following equations are stated:


And at the end this is written:


So my question would be, why cant we get (calculate) s²_wT from the partial replicate design? We obviously get s²_wR and dont we also get s²_w ? So then from the equation marked in yellow in the first picture, we can get s²_wT by: (2* s²_w - s²_wR )? Or am I missing something here?

Best regards
BEQool